country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

112 Results for "

insulin release

" in MedChemExpress (MCE) Product Catalog:

Products (112)

Sort by :

Categories

By Targets

Products

Liraglutide TFA

43 Publications Verification

Cat. No.: HY-P0014B

Target:

GLP Receptor

Research Areas:

Metabolic Disease

Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Glimepiride

8 Cited Publications

Cat. No.: HY-B0104

CAS No.: 93479-97-1

Synonyms: Glimperide; HOE-490

Target:

Amyloid-β Potassium Channel

Research Areas:

Neurological Disease Metabolic Disease

Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED₅₀ of 182 μg/kg. Glimepiride acts at ATPase-dependent potassium channels in β cells of the pancreas to stimulate insulin release.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

8-Bromo-cGMP sodium

8 Cited Publications

Cat. No.: HY-101379A

CAS No.: 51116-01-9

Purity: 99.81%

Target:

Calcium Channel

Research Areas:

Cardiovascular Disease Neurological Disease

8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator. 8-Bromo-cGMP sodium significantly inhibits Ca ²⁺ macroscopic currents and impairs insulin release stimulated with high K ⁺ . 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses .

Compare